Jim Middelburg

Dr. Jim Middelburg

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JMJim Middelburg
Jim Middelburg
KKKristel Kemper
Kristel Kemper
PEPatrick Engelberts
Patrick Engelberts
ALAran F. Labrijn
Aran F. Labrijn
JSJanine Schuurman
Janine Schuurman
THThorbald van Hall
Thorbald van Hall
Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities, sparse T-cell infiltration and impaired T-cell quality due to the presence of an immunosuppressive tumor microenvironment, which affect the safety and limit efficacy of CD3-bispecific antibody therapy. In this review, we provide a brief status update of the CD3-bispecific antibody therapy field and identify intrinsic hurdles in solid cancers. Furthermore, we describe potential combinatorial approaches to overcome these challenges in order to generate selective and more effective responses.

2 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
ACAmanda X. Y. Chen
Amanda X. Y. Chen
KYKah Min Yap
Kah Min Yap
JKJoelle S. Kim
Joelle S. Kim
KSKevin Sek
Kevin Sek
YHYu-Kuan Huang
Yu-Kuan Huang
PBPaul Beavis
Paul Beavis
The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumours is limited by immunosuppression and antigen heterogeneity1,2,3. To overcome these barriers, ‘armoured’ CAR T cells, which secrete proinflammatory cytokines, have been developed4. However, their clinical application has been limited because of toxicity related to peripheral expression of the armouring transgene5. Here, we have developed a CRISPR knock-in strategy that leverages the regulatory mechanisms of endogenous genes to drive transgene expression in a tumour-localized manner. By screening endogenous genes with tumour-restricted expression, we have identified the NR4A2 and RGS16 promoters as promising candidates to support the delivery of cytokines such as IL-12 and IL-2 directly to the tumour site, leading to enhanced antitumour efficacy and long-term survival of mice in both syngeneic and xenogeneic models. This effect was concomitant with improved CAR T cell polyfunctionality, activation of endogenous antitumour immunity and a favourable safety profile, and was applicable in CAR T cells from patients.

2 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJim Middelburg
Jim Middelburg
MSMarjolein Sluijter
Marjolein Sluijter
GSGaby Schaap
Gaby Schaap
BGBüşra Göynük
Büşra Göynük
KLKaty Lloyd
Katy Lloyd
THThorbald van Hall
Thorbald van Hall
CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell infiltrate. Here, we show that pre-treatment vaccination, even when composed of tumor-unrelated antigens, induces CXCR3-mediated T-cell influx in immunologically ‘cold’ tumor models in male mice. In the absence of CD3 bsAb, the infiltrate is confined to the tumor invasive margin, whereas subsequent CD3 bsAb administration induces infiltration of activated effector CD8 T cells into the tumor cell nests. This combination therapy installs a broadly inflamed Th1-type tumor microenvironment, resulting in effective tumor eradication. Multiple vaccination formulations, including synthetic long peptides and viruses, empower CD3 bsAb therapy. Our results imply that eliciting tumor infiltration with vaccine-induced tumor-(un)related T cells can greatly improve the efficacy of CD3 bsAbs in solid tumors.

3 December 2023 in Cell Reports
Verified
Journal Article
Open access
JMJim Middelburg
Jim Middelburg
SGSoroush Ghaffari
Soroush Ghaffari
TSTom A.W. Schoufour
Tom A.W. Schoufour
MSMarjolein Sluijter
Marjolein Sluijter
GSGaby Schaap
Gaby Schaap
THThorbald van Hall
Thorbald van Hall
The immune checkpoint NKG2A/CD94 is a promising target for cancer immunotherapy, and its ligand major histocompatibility complex E (MHC-E) is frequently upregulated in cancer. NKG2A/CD94-mediated inhibition of lymphocytes depends on the presence of specific leader peptides in MHC-E, but when and where they are presented in situ is unknown. We apply a nanobody specific for the Qdm/Qa-1b complex, the NKG2A/CD94 ligand in mouse, and find that presentation of Qdm peptide depends on every member of the endoplasmic reticulum-resident peptide loading complex. With a turnover rate of 30 min, the Qdm peptide reflects antigen processing capacity in real time. Remarkably, Qdm/Qa-1b complexes require inflammatory signals for surface expression in situ, despite the broad presence of Qa-1b molecules in homeostasis. Furthermore, we identify LILRB1 as a functional inhibition receptor for MHC-E in steady state. These data provide a molecular understanding of NKG2A blockade in immunotherapy and assign MHC-E as a convergent ligand for multiple immune checkpoints.

1 May 2022 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
SGSoroush Ghaffari
Soroush Ghaffari
KUKatherine Upchurch-Ange
Katherine Upchurch-Ange
SGSusanne Gimlin
Susanne Gimlin
Trivendra TripathiTrivendra Tripathi
Trivendra Tripathi
MSMarjolein Sluijter
Marjolein Sluijter
JWJon Weidanz
Jon Weidanz
The NKG2A/HLA-E axis is an immune checkpoint that suppresses immune effector activity in the tumor microenvironment. In mice, the ligand for the NKG2A/CD94 inhibitory receptor is the nonclassical MHC molecule Qa-1b, the HLA-E ortholog, which presents the peptide AMAPRTLLL, referred to as Qdm (for Qa-1 determinant modifier). This dominant peptide is derived from the leader sequences of murine classical MHC class I encoded by the H-2D and -L loci. To broaden our understanding of Qa-1b/Qdm peptide complex biology and its tumor protective role, we identified a TCR-like Ab from a single domain VHH library using yeast surface display. The TCR-like Ab (EXX-1) binds only to the Qa-1b/Qdm peptide complex and not to Qa-1b alone or Qa-1b loaded with control peptides. Conversely, currently available Abs to Qa-1b bind independent of peptide loaded. Flow cytometric results revealed that EXX-1 selectively bound to Qa-1b/Qdm-positive B16F10, RMA, and TC-1 mouse tumor cells but only after pretreatment with IFN-γ; no binding was observed following genetic knockdown of Qa-1b or Qdm peptide. Furthermore, EXX-1 Ab blockade promoted NK cell–mediated tumor cell lysis in vitro. Our findings show that EXX-1 has exquisite binding specificity for the Qa-1b/Qdm peptide complex, making it a valuable research tool for further investigation of the Qa-1b/Qdm peptide complex expression and regulation in healthy and diseased cells and for evaluation as an immune checkpoint blocking Ab in syngeneic mouse tumor models. Key Points A llama was immunized with Qa-1b/Qdm, ligand for NKG2A, to construct a VHH library. A single-domain TCR-like Ab, EXX-1, specific for Qa-1b/Qdm, was identified. EXX-1 selectively blocks the NKG2A/Qa-1b axis to promote NK lysis of target cells.

9 April 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
AHAngela F. el Hebieshy
Angela F. el Hebieshy
ZWZacharias Wijfjes
Zacharias Wijfjes
CGCamille M. Le Gall
Camille M. Le Gall
JMJim Middelburg
Jim Middelburg
KRKim Elisa De Roode
Kim Elisa De Roode
FSFerenc A Scheeren
Ferenc A Scheeren
Antibody conjugates are the foundation of a wide range of diagnostic and therapeutic applications. Although many antibody-conjugation techniques are robust and efficient, obtaining homogeneous multimeric conjugation products remains challenging. Here we report a modular and versatile technique for the site-directed multivalent conjugation of antibodies via the small-protein ubiquitin. Specifically, multiple ubiquitin fusions with antibodies, antibody fragments, nanobodies, peptides or small molecules such as fluorescent dyes can be conjugated to antibodies and nanobodies within 30 min. The technique, which we named ‘ubi-tagging’, allowed us to efficiently generate a bispecific T-cell engager as well as nanobodies conjugated to dendritic-cell-targeted antigens that led to potent T-cell responses. Using both recombinant ubi-tagged proteins and synthetic ubiquitin derivatives allows for the iterative, site-directed and multivalent conjugation of antibodies and nanobodies to a plethora of molecular moieties.